Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published March 21, 2022 | Published
Journal Article Open

Solving neurodegeneration: common mechanisms and strategies for new treatments

Abstract

Across neurodegenerative diseases, common mechanisms may reveal novel therapeutic targets based on neuronal protection, repair, or regeneration, independent of etiology or site of disease pathology. To address these mechanisms and discuss emerging treatments, in April, 2021, Glaucoma Research Foundation, BrightFocus Foundation, and the Melza M. and Frank Theodore Barr Foundation collaborated to bring together key opinion leaders and experts in the field of neurodegenerative disease for a virtual meeting titled "Solving Neurodegeneration". This "think-tank" style meeting focused on uncovering common mechanistic roots of neurodegenerative disease and promising targets for new treatments, catalyzed by the goal of finding new treatments for glaucoma, the world's leading cause of irreversible blindness and the common interest of the three hosting foundations. Glaucoma, which causes vision loss through degeneration of the optic nerve, likely shares early cellular and molecular events with other neurodegenerative diseases of the central nervous system. Here we discuss major areas of mechanistic overlap between neurodegenerative diseases of the central nervous system: neuroinflammation, bioenergetics and metabolism, genetic contributions, and neurovascular interactions. We summarize important discussion points with emphasis on the research areas that are most innovative and promising in the treatment of neurodegeneration yet require further development. The research that is highlighted provides unique opportunities for collaboration that will lead to efforts in preventing neurodegeneration and ultimately vision loss.

Additional Information

© The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Received 17 November 2021. Accepted 18 February 2022. Published 21 March 2022. The authors would like to acknowledge additional participants of the "Solving Neurodegeneration Catalyst Meeting" held virtually over several sessions in April 2021, including Ted and Terrence Barr, Aaron Gitler, Yang Hu, Nicholas Marsh-Armstrong, Arnon Rosenthal, and Donna Wilcock. We thank them for sharing their innovative research and ideas during the event. We are indebted to the generosity and staff of the Melza M. and Frank Theodore Barr Foundation, Glaucoma Research Foundation, and the BrightFocus Foundation for their support of this meeting. Figures for this review were created with BioRender.com. Funding for the "Solving Neurodegeneration Catalyst Meeting" and associated sessions was provided by BrightFocus Foundation, Glaucoma Research Foundation, and the Melza M. and Frank Theodore Barr Foundation. Availability of data and materials. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Contributions. All authors conceived the ideas and concepts written in this review. LKW wrote the main text. LKW and DJC organized the main body of the text. SAL, ST, LB, ADP, CW, JLG, ZH, XD, GB, AAD, KS, ALT, DCC, MVCS, JGF, PS, SR, TB and DEB all provided substantial edits and expertise. All authors read and approved the final manuscript. Ethics approval and consent to participate: N/A. Consent for publication: N/A. The authors declare that there are no competing interests.

Attached Files

Published - s13024-022-00524-0.pdf

Files

s13024-022-00524-0.pdf
Files (3.2 MB)
Name Size Download all
md5:930110361c78c2ecb8b06a2019bf7ae0
3.2 MB Preview Download

Additional details

Created:
August 22, 2023
Modified:
December 22, 2023